Lessons learned from the clinical development of oral peptides

British Journal of Clinical Pharmacology

Volumn 79, Issue 5, 2015, Pages 720-732

  Karsdal, Morten Asser ^a   Riis, Bente Juul ^a   Mehta, Nozer ^b   Stern, William ^b   Arbit, Ehud ^c   Christiansen, Claus ^a   Henriksen, Kim ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b Enteris Biopharma Inc   (United States)

^c Oramed Pharmaceuticals   (Israel)

Author keywords

bone; calcitonin; cartilage; clinical trial; diabetes; oral formulation

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; INSULIN; PARATHYROID HORMONE[1-34]; PEPTIDE YY [3-36]; RECOMBINANT PARATHYROID HORMONE; SALCATONIN; DRUG CARRIER; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ARTICLE; CIRCADIAN RHYTHM; CLINICAL STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; ENHANCER REGION; HUMAN; INTESTINE MUCOSA PERMEABILITY; MACROMOLECULE; PRIORITY JOURNAL; CHEMISTRY; GASTROINTESTINAL ABSORPTION; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES;

ADMINISTRATION, ORAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL ABSORPTION; HUMANS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84928339215     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12557     Document Type: Article

References (100)

1. Van den Mooter G,. Colon drug delivery. Expert Opin Drug Deliv 2006; 3: 111-125.
2. Shareef MA, Khar RK, Ahuja A, Ahmad FJ, Raghava S,. Colonic drug delivery: an updated review. AAPS PharmSci 2003; 5: E17.
3. Otvos L Jr, Wade JD,. Current challenges in peptide-based drug discovery. Front Chem 2014; 2: 62.
4. Mustata G, Dinh SM,. Approaches to oral drug delivery for challenging molecules. Crit Rev Ther Drug Carrier Syst 2006; 23: 111-135.
5. Mustata G, Dinh SM,. Drug delivery global summit-evaluating emerging technologies. Expert Opin Drug Deliv 2005; 2: 185-187.
6. Karsdal MA, Henriksen K, Bay-Jensen AC, Molloy B, Arnold M, John MR, Byrjalsen I, Azria M, Riis BJ, Qvist P, Christiansen C,. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharmacol 2011; 51: 460-471.
7. http://products.sanofi.us/DDAVPTablet/DDAVP-Tablets.pdf
8. Yamamoto M, Tachikawa S, Maeno H,. Effects of porcine calcitonin on behavioral and electrophysiological responses elicited by electrical stimulation of the tooth pulp in rabbits. Pharmacology 1982; 24: 337-345.
9. Lee YH, Sinko PJ,. Oral delivery of salmon calcitonin. Adv Drug Deliv Rev 2000; 42: 225-238.
10. Torres-Lugo M, Peppas NA,. Transmucosal delivery systems for calcitonin: a review. Biomaterials 2000; 21: 1191-1196.
11. Buclin T, Cosma RM, Burckhardt P, Azria M, Attinger M,. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 2002; 17: 1478-1485.
12. Sakuma S, Suzuki N, Sudo R, Hiwatari K, Kishida A, Akashi M,. Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int J Pharm 2002; 239: 185-195.
13. Guggi D, Kast CE, Bernkop-Schnurch A,. In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm Res 2003; 20: 1989-1994.
14. Wang J, Chow D, Heiati H, Shen WC,. Reversible lipidization for the oral delivery of salmon calcitonin. J Control Release 2003; 88: 369-380.
15. Tanko LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C,. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 2004; 19: 1531-1538.
16. Bernkop-Schnurch A, Hoffer MH, Kafedjiiski K,. Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin Drug Deliv 2004; 1: 87-98.
17. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y,. pH-sensitive microsphere delivery increases oral bioavailability of calcitonin. J Control Release 2004; 98: 1-9.
18. Bagger YZ, Tanko LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L, Azria M, Christiansen C,. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005; 37: 425-430.
19. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP,. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006; 54: 3205-3211.
20. Sondergaard BC, Oestergaard S, Christiansen C, Tanko LB, Karsdal MA,. The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum 2007; 56: 2674-2678.
21. Araujo F, Fonte P, Santos HA, Sarmento B,. Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control? J Diabetes Sci Technol 2012; 6: 1486-1497.
22. Streubel A, Siepmann J, Bodmeier R,. Gastroretentive drug delivery systems. Expert Opin Drug Deliv 2006; 3: 217-233.
23. Werle M, Makhlof A, Takeuchi H,. Oral protein delivery: a patent review of academic and industrial approaches. Recent Pat Drug Deliv Formul 2009; 3: 94-104.
24. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14. Br J Pharmacol 170: 1449-1867.
25. Hammerle SP, Mindeholm L, Launonen A, Kiese B, Loeffler R, Harfst E, Azria M, Arnold M, John MR,. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. Bone 2012; 50: 965-973.
26. Steinert RE, Poller B, Castelli MC, Friedman K, Huber AR, Drewe J, Beglinger C,. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther 2009; 86: 644-650.
27. Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK,. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 2013; 447: 75-93.
28. Park K, Kwon IC, Park K,. Oral protein delivery: current status and future prospects. Reactive Funct Polym 2011; 71: 280-287.
29. Salehi M, Gastaldelli A, D'Alessio DA,. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology 2014; 146: 669-680.
30. Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I,. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv 2005; 2: 191-197.
31. Leone-Bay A, Santiago N, Achan D, Chaudhary K, DeMorin F, Falzarano L, Haas S, Kalbag S, Kaplan D, Leipold H,. N-acylated alpha-amino acids as novel oral delivery agents for proteins. J Med Chem 1995; 38: 4263-4269.
32. Mlynek GM, Calvo LJ, Robinson JR,. Carrier-enhanced human growth hormone absorption across isolated rabbit intestinal tissue. Int J Pharm 2000; 197: 13-21.
33. Wu SJ, Robinson JR,. Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone. Pharm Res 1999; 16: 1266-1272.
34. Karsdal MA, Byrjalsen I, Azria M, Arnold M, Choi L, Riis BJ, Christiansen C,. Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br J Clin Pharmacol 2009; 67: 413-420.
35. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C,. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin. BMC Clin Pharmacol 2008; 8: 5.
36. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C,. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin Pharmacol 2008; 8: 12.
37. Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Lau EM, Arnold M, Christiansen C,. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage 2010; 18: 150-159.
38. Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Christiansen C,. Investigations of inter- and intra-individual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy. Eur J Clin Pharmacol 2010; 66: 29-37.
39. Karsdal MA, Henriksen K, Arnold M, Christiansen C,. Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 2008; 22: 137-144.
40. Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Christiansen C,. A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin. J Clin Pharmacol 2009; 49: 229-234.
41. Jusko WJ, Ko HC,. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994; 56: 406-419.
42. Andreassen KV, Hjuler ST, Furness SG, Sexton PM, Christopoulos A, Nosjean O, Karsdal MA, Henriksen K,. Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias. PLoS ONE 2014; 9: e92042.
43. Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S,. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 1998; 63: 102-106.
44. Sostek MB, Chen Y, Andersson T,. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol 2007; 64: 386-390.
45. Lentz KA, Quitko M, Morgan DG, Grace JE Jr, Gleason C, Marathe PH,. Development and validation of a preclinical food effect model. J Pharm Sci 2007; 96: 459-472.
46. Karara AH, Dunning BE, McLeod JF,. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol 1999; 39: 172-179.
47. Henriksen K, Bay-Jensen AC, Christiansen C, Karsdal MA,. Oral salmon calcitonin-pharmacology in osteoporosis. Expert Opin Biol Ther 2010; 10: 1617-1629.
48. Beglinger C, Poller B, Arbit E, Ganzoni C, Gass S, Gomez-Orellana I, Drewe J,. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin Pharmacol Ther 2008; 84: 468-474.
49. Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C,. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr 2010; 92: 810-817.
50. Kapitza C, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T,. Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care 2010; 33: 1288-1290.
51. Lee YH, Perry BA, Labruno S, Lee HS, Stern W, Falzone LM, Sinko PJ,. Impact of regional intestinal pH modulation on absorption of peptide drugs: oral absorption studies of salmon calcitonin in beagle dogs. Pharm Res 1999; 16: 1233-1239.
52. Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alexandersen P, Byrjalsen I, Valter I, Nedergaard BS, Teglbjaerg CS, Stern W, Sturmer A, Mitta S, Nino AJ, Fitzpatrick LA, Christiansen C, Karsdal MA,. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Bone 2013; 53: 160-166.
53. Sturmer A, Mehta N, Giacchi J, Cagatay T, Tavakkol R, Mitta S, Fitzpatrick L, Wald J, Trang J, Stern W,. Pharmacokinetics of oral recombinant human parathyroid hormone [(1-31)NH(2)] in postmenopausal women with osteoporosis. Clin Pharmacokinet 2013; 52: 995-1004.
54. Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the ORACAL trial. J Bone Miner Res 2012; 27: 1821-1829.
55. Doi N, Tomita M, Hayashi M,. Absorption enhancement effect of acylcarnitines through changes in tight junction protein in Caco-2 cell monolayers. Drug Metab Pharmacokinet 2011; 26: 162-170.
56. Watson CJ, Rowland M, Warhurst G,. Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. Am J Physiol Cell Physiol 2001; 281: C388-C397.
57. Linnankoski J, Makela J, Palmgren J, Mauriala T, Vedin C, Ungell AL, Lazorova L, Artursson P, Urtti A, Yliperttula M,. Paracellular porosity and pore size of the human intestinal epithelium in tissue and cell culture models. J Pharm Sci 2010; 99: 2166-2175.
58. http://caratherapeutics.com/
59. Stern W, Mehta N, Carl S,. Oral delivery of peptides by PeptelligenceTM technology. Drug Dev Deliv 2013; 13: 38-42.
60. Binkley N, Bone HG, Bolognese MA, Krause DS,. Safety and efficacy of orally administered recombinant salmon calcitonin tablets in the prevention of postmenopausal osteoporosis in women with low bone mass: a phase 2 placebo-controlled trial. Presentation number: 1233. J Bone Miner Res 2012; 27: 1821-1829.
61. Amidon GL, Lee HJ,. Absorption of peptide and peptidomimetic drugs. Annu Rev Pharmacol Toxicol 1994; 34: 321-341.
62. Marschutz MK, Bernkop-Schnurch A,. Oral peptide drug delivery: polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro. Biomaterials 2000; 21: 1499-1507.
63. Radwan MA, Aboul-Enein HY,. The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. J Microencapsul 2002; 19: 225-235.
64. Laskowski M Jr, Haessler HA, Miech RP, Peanasky RJ, Laskowski M,. Effect of trypsin inhibitor on passage of insulin across the intestinal barrier. Science 1958; 127: 1115-1116.
65. Fujii S, Yokoyama T, Ikegaya K, Sato F, Yokoo N,. Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J Pharm Pharmacol 1985; 37: 545-549.
66. Tozaki H, Emi Y, Horisaka E, Fujita T, Yamamoto A, Muranishi S,. Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat faecal contents: implications in peptide delivery to the colon. J Pharm Pharmacol 1997; 49: 164-168.
67. Yamamoto A, Taniguchi T, Rikyuu K, Tsuji T, Fujita T, Murakami M, Muranishi S,. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res 1994; 11: 1496-1500.
68. Agarwal V, Nazzal S, Reddy IK, Khan MA,. Transport studies of insulin across rat jejunum in the presence of chicken and duck ovomucoids. J Pharm Pharmacol 2001; 53: 1131-1138.
69. Zhou KSM, Lutterodt H, Whent M, Eskin M, Yu L,. Biochemistry of Foods, 3rd edn. Amsterdam: Academic Press-Elsevier, 2013.
70. Eldor R, Kidron M, Arbit E,. Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects. Diabetes Obes Metab 2010; 12: 219-223.
71. Eldor R, Arbit E, Corcos A, Kidron M,. Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS ONE 2013; 8: e59524.
72. Khedkar A, Iyer H, Anand A, Verma M, Krishnamurthy S, Savale S, Atignal A,. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes Obes Metab 2010; 12: 659-664.
73. Leonard TW, Lynch J, McKenna MJ, Brayden DJ,. Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin Drug Deliv 2006; 3: 685-692.
74. Walsh EG, Adamczyk BE, Chalasani KB, Maher S, O'Toole EB, Fox JS, Leonard TW, Brayden DJ,. Oral delivery of macromolecules: rationale underpinning Gastrointestinal Permeation Enhancement Technology (GIPET). Ther Deliv 2011; 2: 1595-1610.
75. http://www.merrionpharma.com
76. Rosenmayr-Templeton L,. The oral delivery of peptides and proteins: established versus recently patented approaches. Pharm Pat Anal 2013; 2: 125-145.
77. Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D, Landau I, Karmeli I, Bidlingmaier M, Strasburger CJ, Kleinberg DL, Melmed S, Mamluk R,. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012; 97: 2362-2369.
78. http://www.clinicaltrials.gov
79. Vidgren MT, Kublik H,. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 1998; 29: 157-177.
80. Fransen N, Bredenberg S, Bjork E,. Clinical study shows improved absorption of desmopressin with novel formulation. Pharm Res 2009; 26: 1618-1625.
81. Davis GA, Rudy AC, Archer SM, Wermeling DP, McNamara PJ,. Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. Pharmacotherapy 2004; 24: 26-32.
82. Smart AL, Gaisford S, Basit AW,. Oral peptide and protein delivery: intestinal obstacles and commercial prospects. Expert Opin Drug Deliv 2014; 11: 1323-1335.
83. Cheng W, Lim LY,. Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol. J Pharm Sci 2009; 98: 1438-1451.
84. Cheng W, Lim LY,. Lipeo-sCT: a novel reversible lipidized salmon calcitonin derivative, its biophysical properties and hypocalcemic activity. Eur J Pharm Sci 2009; 37: 151-159.
85. Cheng W, Satyanarayanajois S, Lim LY,. Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity. Pharm Res 2007; 24: 99-110.
86. Woodley JF,. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst 1994; 11: 61-95.
87. Bernkop-Schnurch A,. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release 1998; 52: 1-16.
88. Mahato RI, Narang AS, Thoma L, Miller DD,. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 2003; 20: 153-214.
89. Kidron M, Dinh S, Menachem Y, Abbas R, Variano B, Goldberg M, Arbit E, Bar-On H,. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet Med 2004; 21: 354-357.
90. Nissan A, Ziv E, Kidron M, Bar-On H, Friedman G, Hyam E, Eldor A,. Intestinal absorption of low molecular weight heparin in animals and human subjects. Haemostasis 2000; 30: 225-232.
91. Ziv E, Kidron M, Raz I, Krausz M, Blatt Y, Rotman A, Bar-On H,. Oral administration of insulin in solid form to nondiabetic and diabetic dogs. J Pharm Sci 1994; 83: 792-794.
92. Bendayan M, Ziv E, Gingras D, Ben-Sasson R, Bar-On H, Kidron M,. Biochemical and morpho-cytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa. Diabetologia 1994; 37: 119-126.
93. Kidron M, Bar-On H, Berry EM, Ziv E,. The absorption of insulin from various regions of the rat intestine. Life Sci 1982; 31: 2837-2841.
94. Bakhru SH, Furtado S, Morello AP, Mathiowitz E,. Oral delivery of proteins by biodegradable nanoparticles. Adv Drug Deliv Rev 2013; 65: 811-821.
95. Sung HW, Sonaje K, Liao ZX, Hsu LW, Chuang EY,. pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications. Acc Chem Res 2012; 45: 619-629.
96. Damge C, Reis CP, Maincent P,. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv 2008; 5: 45-68.
97. Wong TW,. Chitosan and its use in design of insulin delivery system. Recent Pat Drug Deliv Formul 2009; 3: 8-25.
98. Chalasani KB, Russell-Jones GJ, Jain AK, Diwan PV, Jain SK,. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release 2007; 122: 141-150.
99. Chalasani KB, Russell-Jones GJ, Yandrapu SK, Diwan PV, Jain SK,. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release 2007; 117: 421-429.
100. Karsdal MA, Byrjalsen I, Leeming DJ, Delmas PD, Christiansen C,. The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int 2008; 19: 1355-1361.